MX2021002833A - Sistema de suministro de farmaco transdermico. - Google Patents

Sistema de suministro de farmaco transdermico.

Info

Publication number
MX2021002833A
MX2021002833A MX2021002833A MX2021002833A MX2021002833A MX 2021002833 A MX2021002833 A MX 2021002833A MX 2021002833 A MX2021002833 A MX 2021002833A MX 2021002833 A MX2021002833 A MX 2021002833A MX 2021002833 A MX2021002833 A MX 2021002833A
Authority
MX
Mexico
Prior art keywords
basement membrane
active ingredient
agent
vaso
modulator
Prior art date
Application number
MX2021002833A
Other languages
English (en)
Inventor
Zhen Zhu
John J Masiz
Original Assignee
Biophysics Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biophysics Pharma Inc filed Critical Biophysics Pharma Inc
Publication of MX2021002833A publication Critical patent/MX2021002833A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a sistemas de suministro transdérmico, métodos y kits que incluyen un agente para penetrar la membrana basal, una membrana de la piel previamente conocida por ser difícil de penetrar. En particular, la formulación incluye un disruptor de membrana basal que desnaturaliza de manera reversible la membrana basal de la piel. La formulación de la presente invención también incluye que tiene al menos un agente de penetración, al menos un vasomodulador, y al menos un ingrediente activo. En una modalidad, el agente de penetración incluye un disolvente, un agente lipofílico, un agente hidrofílico, en donde el disruptor de membrana basal, el vasomodulador, y al ingrediente activo pasar a través del estrato córneo y epidermis. El disruptor de membrana basal permite al vasomodulador y al ingrediente activo pasar a través de la membrana basal a la dermis. El ingrediente activo, una vez en la dermis, es suministrado localmente al tejido o sistemáticamente al torrente sanguíneo.
MX2021002833A 2018-09-27 2019-09-25 Sistema de suministro de farmaco transdermico. MX2021002833A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737479P 2018-09-27 2018-09-27
US16/582,922 US11446257B2 (en) 2018-09-27 2019-09-25 Transdermal drug delivery system
PCT/US2019/053000 WO2020069013A1 (en) 2018-09-27 2019-09-25 Transdermal drug delivery system

Publications (1)

Publication Number Publication Date
MX2021002833A true MX2021002833A (es) 2021-05-27

Family

ID=69947952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002833A MX2021002833A (es) 2018-09-27 2019-09-25 Sistema de suministro de farmaco transdermico.

Country Status (5)

Country Link
US (3) US11446257B2 (es)
AU (1) AU2019349935B2 (es)
CA (1) CA3112808A1 (es)
MX (1) MX2021002833A (es)
WO (1) WO2020069013A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446257B2 (en) 2018-09-27 2022-09-20 BioPhysics Pharma, Inc. Transdermal drug delivery system
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903159A (en) 1970-09-17 1975-09-02 Armour Pharma Methanesulfonamidophenyl guanidine compounds
DE69423616T2 (de) 1993-06-23 2000-11-09 John J Masiz Molekulares transdermales transportsystem
US5645854A (en) 1993-06-23 1997-07-08 Masiz; John J. Molecular transdermal transport system
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
US5460821A (en) * 1993-06-23 1995-10-24 Masiz; John J. Molecular transdermal transport system
EP0739200A4 (en) 1993-11-23 1997-12-17 Cambridge Neuroscience Inc SUBSTITUTED GUANIDINES FOR THERAPEUTIC USE
US7351743B1 (en) 1994-02-03 2008-04-01 Wyeth Therapeutic guanidines
ZA95878B (en) 1994-02-03 1996-01-16 Cambridge Neuroscience Inc Therapeutic guanidines
DE69935325T2 (de) 1998-04-21 2007-11-15 Infectio Recherche Inc., Sainte-Foy Formulierungen für die Prävention oder die Behandlung von Krankheiten, die Schleimhäute oder Haut betreffen oder für die Schwangerschaftsverhütung
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
US6914051B1 (en) * 2000-06-28 2005-07-05 David M Allen Penetrating antibiotic gel for soft tissue diseases
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
MXPA04005611A (es) 2001-12-11 2005-04-19 Cellgate Inc Reactivos y conjugados de transporte de guanidinio.
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20060013866A1 (en) * 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US20060062836A1 (en) 2004-09-21 2006-03-23 Carter Stephen G Methods of device-assisted drug delivery
WO2007016766A1 (en) 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
EP2324838A1 (en) 2005-09-12 2011-05-25 Abela Pharmaceuticals, Inc. Compositions Comprising Dimethyl Sulfoxide (DMSO)
WO2007038172A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
WO2007038171A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
US20070185216A1 (en) 2006-02-09 2007-08-09 Marcia Snyder Antiviral method
US9642912B2 (en) * 2006-03-06 2017-05-09 Crescita Therapeutics Inc. Topical formulations for treating skin conditions
US8343486B2 (en) 2008-01-22 2013-01-01 Biochemics, Inc. Methods and compositions for topical treatment of medical conditions including wounds and inflammation
CA2727710C (en) 2008-06-11 2016-11-01 Biochemics, Inc. Control of blood vessel physiology to treat skin disorders
US9724278B2 (en) 2008-06-13 2017-08-08 Colgate-Palmolive Company Oral compositions and uses thereof
EP3574921A1 (en) 2008-09-10 2019-12-04 BioChemics, Inc. Ibuprofen for topical administration
WO2010034019A1 (en) 2008-09-22 2010-03-25 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
EP2352543B1 (en) 2008-12-04 2019-04-03 BioChemics, Inc. Methods and compositions for tattoo removal
WO2011053874A1 (en) 2009-10-30 2011-05-05 Tandem Abela Development Group Llc Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
GB2481630A (en) 2010-07-01 2012-01-04 Robert Taylor Composition for dental health
EP2546244A1 (en) 2011-07-13 2013-01-16 Koste Biochemicals Supercritical process for manufacturing ambradiol, sclareolide and (-)-ambrafuran from sclareol
US20160058725A1 (en) 2013-03-15 2016-03-03 Biochemics, Inc. Topical Formulations and Methods for Drug Delivery
US10226418B2 (en) 2014-05-12 2019-03-12 Susie Q, Ltd. Arginine-containing topical composition
EP3213769A4 (en) 2014-10-30 2018-02-21 Asahi Kasei Kabushiki Kaisha Transdermal-absorption-promoter and transdermal-absorption-promoting supplement
AU2016226280C1 (en) 2015-03-02 2020-09-24 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
CA3011185A1 (en) 2016-01-20 2017-07-27 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
CA3063870A1 (en) 2017-05-15 2018-11-22 Biochemics, Inc. Transdermally-delivered combination drug therapy for pain
US11446257B2 (en) 2018-09-27 2022-09-20 BioPhysics Pharma, Inc. Transdermal drug delivery system
AU2021224149A1 (en) 2020-02-20 2022-09-15 John J. Masiz Transmucosal drug delivery system

Also Published As

Publication number Publication date
WO2020069013A1 (en) 2020-04-02
US20200101025A1 (en) 2020-04-02
AU2019349935A1 (en) 2021-03-18
AU2019349935B2 (en) 2023-01-12
US11446257B2 (en) 2022-09-20
US11865217B2 (en) 2024-01-09
US20220387343A1 (en) 2022-12-08
US20240108588A1 (en) 2024-04-04
BR112021003746A2 (pt) 2021-05-25
CA3112808A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
MX2021002833A (es) Sistema de suministro de farmaco transdermico.
TW200602099A (en) Apparatus and method for transdermal delivery of fentanyl-based agents
Mishra et al. Transdermal drug delivery
WO2005069758A3 (en) Frequency assisted transdermal agent delivery method and system
Paudel et al. Challenges and opportunities in dermal/transdermal delivery
MXPA06013168A (es) Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
WO2005099751A3 (en) Apparatus and method for transdermal delivery of influenza vaccine
DE602005004782T2 (de) Transdermale arzneimittelabgabevorrichtung durch dehnung/lockerung
WO2007028167A3 (en) Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof
EP2001453A4 (en) APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE AGENTS FOR TREATING OR PREVENTING OSTEOPENIA
TW200618830A (en) Micorprojection apparatus and system with low infection potential
WO2005051455A3 (en) Ultrasound assisted transdermal vaccine delivery method and system
ATE304878T1 (de) Mikrostrukturen zur kutanen verabreichung eines mittels auf die haut
WO2010034019A4 (en) Transdermal drug delivery using an osmolyte and vasoactive agent
MXPA03003815A (es) Dispositivos de suministro transdermico de farmaco que tienen microrresaltos recubiertos.
MXPA02005765A (es) Aparato de tratamiento de piel para el suministro de farmaco transdermico sostenido.
BRPI0517501A (pt) dispositivo médico apropriado para uso na administração de um componente ativo na ou através da pele
TW200616660A (en) Apparatus and method for transdermal delivery of natriuretic peptides
US20180369136A1 (en) Devices and methods for transdermal treatment of basal cell carcinoma
TW200621316A (en) Apparatus and method for transdermal delivery of vascular endothelial growth factors
WO2019136033A3 (en) Microneedle delivery system with anchor
TW200738252A (en) Apparatus and method for transdermal delivery of Epoetin-based agents
Yadav et al. Current updates in transdermal therapeutic systems and their role in neurological disorders
CA2569285A1 (en) Methods of device-assisted drug delivery
Deshwal et al. Optimization techniques in transdermal drug delivery system